# A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

> **NCT07628582** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 48 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Malignancies

## Interventions

- **BIOLOGICAL:** LVIVO-TaVec122 product

## Key facts

- **NCT ID:** NCT07628582
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2028-10-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628582, "A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07628582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*